Advanced search
Publication Cover
Expert Opinion on Medical Diagnostics Volume 1, 2007 - Issue 3
Journal homepage
27
Views
2
CrossRef citations to date
0
Altmetric
Review

Biomarkers in Barrett's oesophagus and oesophageal adenocarcinoma

Anna L Paterson MRC Cancer Cell Unit, Hutchison-MRC Research Centre, Hills Road, Cambridge, CB2 0XZ, UK +44 1223 763287; +44 1223 763296; [email protected]
, BA, MB/PhD student &
Rebecca C Fitzgerald MRC Cancer Cell Unit, Hutchison-MRC Research Centre, Hills Road, Cambridge, CB2 0XZ, UK +44 1223 763287; +44 1223 763296; [email protected]
, MA (Cantab) MD FRCP (MRC principal investigator)
Pages 363-376 | Published online: 09 Nov 2007

Bibliography

  • ELLIS IO, BARTLETT J, DOWSETT M et al.: Best Practice No 176: Updated recommendations for HER2 testing in the UK. J. Clin. Pathol. (2004) 57(3):233-237.
  • RIEDINGER J, BONNETAIN F, BASUYAU J et al.: Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann. Oncol. (2007) 18(5):881-885.
  • PEPE MS, ETZIONI R, FENG Z et al.: Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst. (2001) 93(14):1054-1061.
  • LIU R, WANG X, CHEN GY et al.: The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. (2007) 356(3):217-226.
  • DEI TOS AP, ELLIS I: Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods? Eur. J. Cancer (2005) 41(10):1383-1392.
  • LAAKSO M, TANNER M, ISOLA J: Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours. J. Pathol. (2006) 210(1):3-9.
  • CASSON AG, TAMMEMAGI M, ESKANDARIAN S et al.: p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. Mol. Pathol. (1998) 51(2):71-79.
  • RIBEIRO U Jr, FINKELSTEIN SD, SAFATLE-RIBEIRO AV et al.: p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer (1998) 83(1):7-18.
  • PAEZ JG, JANNE PA, LEE JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304(5676):1497-1500.
  • BENVENUTI S, SARTORE-BIANCHI A, DI NICOLANTONIO F et al.: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. (2007) 67(6):2643-2648.
  • HERNANDEZ-BOUSSARD T, RODRIGUEZ-TOME P, MONTESANO R, HAINAUT P: IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International agency for research on cancer. Hum. Mutat. (1999) 14(1):1-8.
  • MURRAY L, SEDO A, SCOTT M et al.: TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut (2006) 55(10):1390-1397.
  • RONKAINEN J, ARO P, STORSKRUBB T et al.: Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology (2005) 129(6):1825-1831.
  • SHAHEEN NJ, CROSBY MA, BOZYMSKI EM, SANDLER RS: Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology (2000) 119(2):333-338.
  • ANDERSON LA, MURRAY LJ, MURPHY SJ et al.: Mortality in Barrett's oesophagus: results from a population based study. Gut (2003) 52(8):1081-1084.
  • FITZGERALD RC: Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut (2006) 55(12):1810-1818.
  • VAN SANDICK JW, VAN LANSCHOT JJ, KUIKEN BW et al.: Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut (1998) 43(2):216-222.
  • GASTROENTEROLOGY BSO: Guidelines for the diagnosis and management of Barrett's columnar lined oesophagus (2005).
  • SAMPLINER RE: Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am. J. Gastroenterol. (2002) 97(8):1888-1895.
  • OVERHOLT BF, LIGHTDALE CJ, WANG KK et al.: Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized Phase III trial. Gastrointest. Endosc. (2005) 62(4):488-498.
  • INADOMI JM, SAMPLINER R, LAGERGREN J et al.: Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann. Intern. Med. (2003) 138(3):176-186.
  • SAEIAN K, STAFF DM, VASILOPOULOS S et al.: Unsedated transnasal endoscopy accurately detects Barrett's metaplasia and dysplasia. Gastrointest. Endosc. (2002) 56(4):472-478.
  • HALUM SL, POSTMA GN, BATES DD, KOUFMAN JA: Incongruence between histologic and endoscopic diagnoses of Barrett's esophagus using transnasal esophagoscopy. Laryngoscope (2006) 116(2):303-306.
  • LAO-SIRIEIX P, O'DONOVAN M, GARDINER S, DEBIRAM I, FITZGERALD R: Development and evaluation of a non-endoscopic immunocytological test for Barrett's oesophagus. J. Clin. Gastoenterol. (2006) 40(Suppl. 4):S191.
  • LAO-SIRIEIX P, ROUS B, O'DONOVAN M et al.: Non-endoscopic immunocytological screening test for Barrett's oesophagus. Gut (2007) 56(7):1033-1034.
  • DIMITROVA DS, TODOROV IT, MELENDY T, GILBERT DM: Mcm2, but not RPA, is a component of the mammalian early G1-phase prereplication complex. J. Cell Biol. (1999) 146(4):709-722.
  • DAVIES RJ, FREEMAN A, MORRIS LS et al.: Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet (2002) 359(9321):1917-1919.
  • WILLIAMS GH, ROMANOWSKI P, MORRIS L et al.: Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. Proc. Natl. Acad. Sci. USA (1998) 95(25):14932-14937.
  • REID BJ, LEVINE DS, LONGTON G, BLOUNT PL, RABINOVITCH PS: Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am. J. Gastroenterol. (2000) 95(7):1669-1676.
  • BUTTAR NS, WANG KK, SEBO TJ et al.: Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology (2001) 120(7):1630-1639.
  • DAR MS, GOLDBLUM JR, RICE TW, FALK GW: Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy? Gut (2003) 52(4):486-489.
  • SRIVASTAVA MD, HORNICK JL, XIAOHONG L et al.: Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus. Am. J. Gastroenterol. (2007) 102:483-493.
  • MONTGOMERY E, BRONNER MP, GOLDBLUM JR et al.: Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum. Pathol. (2001) 32(4):368-378.
  • ORMSBY AH, PETRAS RE, HENRICKS WH et al.: Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut (2002) 51(5):671-676.
  • WONG DJ, PAULSON TG, PREVO LJ et al.: p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res. (2001) 61(22):8284-8289.
  • BLOUNT PL, GALIPEAU PC, SANCHEZ CA et al.: 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res. (1994) 54(9):2292-2295.
  • REID BJ, PREVO LJ, GALIPEAU PC et al.: Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am. J. Gastroenterol. (2001) 96(10):2839-2848.
  • PAULSON TG, GALIPEAU PC, REID BJ: Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR. Genome Res. (1999) 9(5):482-491.
  • WONGSURAWAT VJ, FINLEY JC, GALIPEAU PC et al.: Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: implications for biomarker validation. Cancer Epidemiol. Biomark. Prev. (2006) 15(3):509-516.
  • BANI-HANI K, MARTIN IG, HARDIE LJ et al.: Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J. Natl. Cancer Inst. (2000) 92(16):1316-1321.
  • GALIPEAU PC, COWAN DS, SANCHEZ CA et al.: 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc. Natl. Acad. Sci. USA (1996) 93(14):7081-7084.
  • YU C, ZHANG X, HUANG Q, KLEIN M, GOYAL RK: High-fidelity DNA histograms in neoplastic progression in Barrett's esophagus. Lab. Invest. (2007) 87(5):466-472.
  • DOAK SH, JENKINS GJ, PARRY EM et al.: Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus. Gut (2003) 52(5):623-628.
  • CESTARI R, VILLANACCI V, ROSSI E et al.: Fluorescence in situ hybridisation to evaluate dysplasia in Barrett's esophagus: a pilot study. Cancer Lett. (2007).
  • GALIPEAU PC: A panel of molecular and cytometric markers in Barrett's esophagus predicts progression to esophageal adenocarcinoma. Gastroenterology (2004) 126 (Suppl. 2):A82 (Abstract).
  • MALEY CC, GALIPEAU PC, LI X et al.: The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res. (2004) 64(20):7629-7633.
  • GRAY MR, HALL PA, NASH J et al.: Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. Gastroenterology (1992) 103(6):1769-1776.
  • HONG MK, LASKIN WB, HERMAN BE et al.: Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus. Cancer (1995) 75(2):423-429.
  • GOING JJ, KEITH WN, NEILSON L et al.: Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa. Gut (2002) 50(3):373-377.
  • SIRIEIX P, O'DONOVAN M, BROWN J et al.: Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk fro developing adenocarcinoma in Barrett's esophagus. Clin. Cancer Res. (2003) 9:2560-2566.
  • RODINS K, CHEALE M, COLEMAN N, FOX SB: Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: relationship to tumor dormancy and potential clinical utility. Clin. Cancer Res. (2002) 8(4):1075-1081.
  • GONZALEZ MA, PINDER SE, CALLAGY G et al.: Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. J. Clin. Oncol. (2003) 21(23):4306-4313.
  • HUNT DP, FREEMAN A, MORRIS LS et al.: Early recurrence of benign meningioma correlates with expression of mini-chromosome maintenance-2 protein. Br. J. Neurosurg. (2002) 16(1):10-15.
  • LAO-SIRIEIX P, LOVAT L, FITZGERALD RC: Cyclin A immunocytology as a risk stratificataion tool for Barrett's esophagus surveillance. Clin. Cancer Res. (2007) 13(2):659-665.
  • LIN L, PRESCOTT MS, ZHU Z et al.: Identification and characterization of a 19q12 amplicon in esophageal adenocarcinomas reveals cyclin E as the best candidate gene for this amplicon. Cancer Res. (2000) 60(24):7021-7027.
  • SARBIA M, BEKTAS N, MULLER W et al.: Expression of cyclin E in dysplasia, carcinoma, and nonmalignant lesions of Barrett esophagus. Cancer (1999) 86(12):2597-2601.
  • EADS CA, LORD RV, KURUMBOOR SK et al.: Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res. (2000) 60(18):5021-5026.
  • EADS CA, LORD RV, WICKRAMASINGHE K et al.: Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. (2001) 61(8):3410-3418.
  • WONG NA, WILDING J, BARTLETT S et al.: CDX1 is an important molecular mediator of Barrett's metaplasia. Proc. Natl. Acad. Sci. USA (2005) 102(21):7565-7570.
  • ZOU H, MOLINA JR, HARRINGTON JJ et al.: Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Int. J. Cancer (2005) 116(4):584-591.
  • KUESTER D, DAR AA, MOSKALUK CC et al.: Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression. Neoplasia (2007) 9(3):236-245.
  • BAUMANN S, KELLER G, PUHRINGER F et al.: The prognostic impact of O6-methylguanine-DNA Methyltransferase (MGMT) promotor hypermethylation in esophageal adenocarcinoma. Int. J. Cancer (2006) 119(2):264-268.
  • SCHULMANN K, STERIAN A, BERKI AT et al.: Inactivataion of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene (2005) 24:4138-4148.
  • CLEMENT G, BRAUNSCHWEIG R, PASQUIER N, BOSMAN FT, BENHATTAR J: Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation. J. Pathol. (2006) 208(1):100-107.
  • FARROW DC, VAUGHAN TL, HANSTEN PD et al.: Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomark. Prev. (1998) 7(2):97-102.
  • THUN MJ, NAMBOODIRI MM, HEATH CW Jr: Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. (1991) 325(23):1593-1596.
  • GALIPEAU PC, LI X, BLOUNT PL et al.: NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. (2007) 4(2):E67.
  • SHARMA P: Balloon-based, circumferential endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest. Endosc. (2007) 65:185.
  • VAN LAETHEM JL, PENY MO, SALMON I, CREMER M, DEVIERE J: Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut (2000) 46(4):574-577.
  • KRISHNADATH KK, WANG KK, TANIGUCHI K et al.: Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. Gastroenterology (2000) 119(3):624-630.
  • PRASAD GA, WANG KK, HALLING KC et al.: Biomarkers for the therapy of Barrett's Esophagus with High-grade dysplasia. AGA Abstract:A-8.
  • POHL H, WELCH HG: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J. Natl. Cancer Inst. (2005) 97(2):142-146.
  • CANCER RESEARCH UK OCS.
  • LAGERGREN J, BERGSTROM R, LINDGREN A, NYREN O: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. (1999) 340(11):825-831.
  • LAGERGREN J: Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut (2005) 54(Suppl. 1):i1-i5.
  • BURMEISTER BH, SMITHERS BM, GEBSKI V et al.: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled Phase III trial. Lancet Oncol. (2005) 6(9):659-668.
  • KELSEN DP, GINSBERG R, PAJAK TF et al.: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N. Engl. J. Med. (1998) 339(27):1979-1984.
  • MEDICAL RESEARCH COUNCIL OESOPHAGEAL CANCER WORKING GROUP: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet (2002) 359(9319):1727-1733.
  • WALSH TN, NOONAN N, HOLLYWOOD D et al.: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N. Engl. J. Med. (1996) 335(7):462-467.
  • PARK JW, KERBEL RS, KELLOFF GJ et al.: Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin. Cancer Res. (2004) 10(11):3885-3896.
  • GREENAWALT DM, DUONG C, SMYTH GK et al.: Gene expression profiling of esophageal cancer: comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. Int. J. Cancer (2007) 120(9):1914-1921.
  • PETRICOIN EF, ARDEKANI AM, HITT BA et al.: Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 359(9306):572-577.
  • WANG WS, LIN JK, CHIOU TJ et al.: Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience. Jpn. J. Clin. Oncol. (2000) 30(1):12-16.
  • WANG JY, LU CY, CHU KS et al.: Prognostic significance of pre- and postoperative serum carcinoembryonic antigen levels in patients with colorectal cancer. Eur. Surg. Res. (2007) 39(4):245-250.
  • KAWAKAMI K, BRABENDER J, LORD RV et al.: Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J. Natl. Cancer Inst. (2000) 92(22):1805-1811.
  • DEANS C, WIGMORE S, PATERSON-BROWN S et al.: Serum parathyroid hormone-related peptide is associated with systemic inflammation and adverse prognosis in gastroesophageal carcinoma. Cancer (2005) 103(9):1810-1818.
  • GUILLEM P, TRIBOULET JP: Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis. Esophagus (2005) 18(3):146-150.
  • LAGARDE SM, TEN KATE FJ, RICHEL DJ, OFFERHAUS GJ, VAN LANSCHOT JJ: Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction. Ann. Surg. Oncol. (2007) 14(2):977-991.
  • MCMANUS DT, OLARU A, MELTZER SJ: Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res. (2004) 64(5):1561-1569.
  • STIEWE T: The p53 family in differentiation and tumorigenesis. Nat. Rev. Cancer (2007) 7(3):165-168.
  • IZZO JG, CORREA AM, WU TT et al.: Pretherapy NF-κB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol. Cancer Ther. (2006) 5(11):2844-2850.
  • RAOUF AA, EVOY DA, CARTON E et al.: Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation. Dis. Esophagus (2003) 16(1):17-23.
  • SAAD RS, EL-GOHARY Y, MEMARI E, LIU YL, SILVERMAN JF: Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Hum. Pathol. (2005) 36(9):955-961.
  • DRIESSEN A, LANDUYT W, PASTOREKOVA S et al.: Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann. Surg. (2006) 243(3):334-340.
  • KRISHNADATH KK, TILANUS HW, VAN BLANKENSTEIN M et al.: Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J. Pathol. (1997) 182(3):331-338.
  • MURRAY GI, DUNCAN ME, O'NEIL P et al.: Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J. Pathol. (1998) 185(3):256-261.
  • ELLIS IO, DOWSETT M, BARTLETT J et al.: Recommendations for HER2 testing in the UK. J. Clin. Pathol. (2000) 53(12):890-892.
  • REICHELT U, DUESEDAU P, TSOURLAKIS MC et al.: Frequent homogeneous her-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod. Pathol. (2007) 2007(20):120-129.
  • SAFRAN: Phase I/II study of trastuzumab, palitaxel, cisplatin and radiation for locally advanced, her2 overexpressing, esophageal adenocarcinoma. Int. J. Biol. Oncol. Phys. (2007) 67(2):405.
  • KWAK EL, JANKOWSKI J, THAYER SP et al.: Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin. Cancer Res. (2006) 12(14 Part 1):4283-4287.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.